Associated Papers
Effect of ABCG2 genetic polymorphisms on the transport of anti-seizure medications in hCMEC/D3 cell lines.
Bora S et al.
Cytotechnology, 2026
rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro.
Yamashita M et al.
International Journal of Molecular Sciences, 2025
The role of ABCG2 in health and disease: Linking cancer therapy resistance and other disorders.
El-Ashmawy NE et al.
Life Sciences, 2025
A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe?
Lyu C et al.
International Journal of Molecular Sciences, 2022
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K et al.
Drug Metabolism and Pharmacokinetics, 2022
Multidrug efflux transporter ABCG2: expression and regulation.
Kukal S et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Medically Important Alterations in Transport Function and Trafficking of ABCG2.
Homolya L
International Journal of Molecular Sciences, 2021
Racial Disparity in Drug Disposition in the Digestive Tract.
Gao S et al.
International Journal of Molecular Sciences, 2021
Identification of Specific Trafficking Defects of Naturally Occurring Variants of the Human ABCG2 Transporter.
Bartos Z et al.
Frontiers in Cell and Developmental Biology, 2021
The ABCG2/BCRP transporter and its variants - from structure to pathology.
Sarkadi B et al.
Febs Letters, 2020
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z et al.
Expert Opinion on Drug Metabolism & Toxicology, 2019
Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics.
Heyes N et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Polymorphisms of ABCG2 and its impact on clinical relevance.
Zhang W et al.
Biochemical and Biophysical Research Communications, 2018
Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N et al.
Pharmaceutical Research, 2017
Rare ER protein misfolding-mistrafficking disorders: Therapeutic developments.
Hegde RN et al.
Tissue & Cell, 2017
Multiple common and rare variants of ABCG2 cause gout.
Higashino T et al.
Rmd Open, 2017
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.
Jiang L et al.
Plos Genetics, 2016
The ABCG2 gene Q141K polymorphism contributes to an increased risk of gout: a meta-analysis of 2185 cases.
Qiu Y et al.
Modern Rheumatology, 2014
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K et al.
Pharmacogenomics and Personalized Medicine, 2014
Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
Schnepf R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2013
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T et al.
Chinese Journal of Cancer, 2012
ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
Nakayama A et al.
Nucleosides, Nucleotides & Nucleic Acids, 2011
Identification of ABCG2 dysfunction as a major factor contributing to gout.
Matsuo H et al.
Nucleosides, Nucleotides & Nucleic Acids, 2011
ABCG2/BCRP dysfunction as a major cause of gout.
Matsuo H et al.
Nucleosides, Nucleotides & Nucleic Acids, 2011
Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.
Nakagawa H et al.
Journal of Pharmaceutical Sciences, 2011
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.
Sugiyama T et al.
Biochemical and Biophysical Research Communications, 2011
Production of cells with targeted integration of gene variants of human ABC transporter for stable and regulated expression using the Flp recombinase system.
Wakabayashi-Nakao K et al.
Methods in Molecular Biology (clifton, N.j.), 2010
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.
Ishikawa T et al.
Advances in Pharmacological Sciences, 2010
Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.
Nakagawa H et al.
The Febs Journal, 2009
Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.
Matsuo H et al.
Science Translational Medicine, 2009
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T et al.
Pharmaceutical Research, 2009
Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation.
Wakabayashi-Nakao K et al.
Advanced Drug Delivery Reviews, 2009
Human ABC transporters ABCG2 (BCRP) and ABCG4.
Koshiba S et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2008
Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Nakagawa H et al.
The Biochemical Journal, 2008
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C et al.
British Journal of Cancer, 2008
In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
Tamura A et al.
Drug Metabolism and Pharmacokinetics, 2007
Identification and functional assessment of BCRP polymorphisms in a Korean population.
Lee SS et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
Tamura A et al.
Cancer Science, 2007
[Genetic polymorphisms of human ABC transporter ABCG2: Porphyria risk and ER quality control].
Wakabayashi K et al.
Seikagaku. the Journal of Japanese Biochemical Society, 2007
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Cascorbi I
Pharmacology & Therapeutics, 2006
Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A et al.
Molecular Pharmacology, 2006
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cervenak J et al.
Cancer Letters, 2006
Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system.
Tamura A et al.
Journal of Experimental Therapeutics & Oncology, 2006
Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
Vethanayagam RR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.
Kobayashi D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C et al.
Pharmaceutical Research, 2004